FENFURO

fenfuro supports healthy glucose levels. Good for diabetes

FENFURO™ is a proprietary product derived from Fenugreek seeds (Trigonella Foenum Graecum) by an innovative process. It is a group of furostanolic saponins that help to maintain healthy blood glucose levels. FENFURO contains a rich variety of saponins and flavonoids. All of these substances are known to play valuable role in maintaining a stable Glucose levels.

Fenfuro is supported by 7 international patents and has also been clinically evaluated on 254 diabetic patients. A further study on 100 patients is underway at AIIMS. The clinical studies have been published in well-known international journals and have won awards in many international conferences.

It is an Over the Counter (OTC) product and has been approved by FSSAI.

  • 100% natural and innovative
  • Extracted naturally from Fenugreek seeds
  • It is a single herb extract without additives and excipients
  • Suitable to maintain blood glucose level
  • Supported by 7 international patents
  • Clinically Evaluated on 154 patients
  • No known side effects
  • Halal and Kosher certified
  • Halal Certified
  • Mitigates the risk of unhealthy blood glucose level
  • Easily digested and readily absorbed
  • Natural Supplement
  • 30 convenient capsules to allow you to take anywhere with you
  • Recommended for everyone to avoid unstable blood glucose level

Description

Clinical Evaluation of FENFURO in Patients with Type-2 Diabetes: An Add-On Study

Study Design

This was multicentric, randomized, Placebo-controlled, double-blind, fixed dose clinical evaluation of Fenugreek seed extract administered orally in patients of Type 2 DM.

Clinical Evaluation of Fenugreek Seed Extract in 154 Patients with Type- 2 Diabetes: An Add-On Study at King George’s Medical University, Lucknow

Efficacy Conclusions

  • A significant decrease in HbA1c levels was observed as compared to respective baseline value and as compared to placebo after weeks.
  • Fenfuro caused significant reduction in the fasting blood sugar levels.
  • Fenfuro caused significant reduction in the post prandial (PP) blood sugar levels as compared to Placebo group as well as compared to respective baseline value.
  • 83% of the patients reported decrease in fasting sugar levels in Fenfuro treated group as compared to 62% in Placebo treated group.
  • 89% of the patients reported decrease in PP sugar levels in Fenfuro treated group as compared to 72% of the patients in the Placebo treated group.
  • 48.8% of the patients reported reduced dosage of anti diabetic therapy in Fenfuro treated group, where as 18.05% of the patients reported reduced dosage of anti diabetic therapy in Placebo treated group.

Safety Conclusions

  • No significant change in serum SGOT, SGPT & ALP activities was observed, indicating investigational product (Fenfuro-fenugreek seed extract) was safe for liver functioning.
  • No significant change in blood urea nitrogen and creatinine levels was observed indicating investigational product (Fenfuro-fenugreek seed extract) was safe for kidney functioning.
  • No significant change in hematological parameters was observed.
  • Keeping hematological and biochemical results in view, investigational product was safe for consumption.

Clinical Evaluation of Fenugreek Seed Extract in 104 Patients with Type- 2 Diabetes: An Add-On Study at Gian Sagar Medical College & Hospital, Banur, Patiala

Efficacy Conclusions

  • Fasting glucose: The mean fasting glucose levels were significantly decreased in FENFURO-treated patients, whereas these levels increased in on-going anti-diabetic therapy-treated patients. FENFURO caused 38.26% decrease in fasting glucose levels on completion of the treatment. Such decrease in fasting glucose levels was observed in 95.2% of the study population on completion of the treatment with FENFURO.
  • Post-prandial (PP) glucose: FENFURO caused significant decrease in PP glucose levels on completion of the treatment as compared to the on-going anti-diabetic therapy-treated population. The decrease in mean PP glucose levels were up to 44.04% in the FENFURO-treated study population on completion of the treatment. As observed on completion of the treatment with FENFURO, 88.10% of study population shown to have decrease in PP glucose levels.
  • Glycated hemoglobin (HbA1c): FENFURO treatment resulted in normalizing the mean HbA1c levels of the study population. The HbA1c levels decreased significantly in the study population of both groups on completion of the treatment. Mean HbA1c levels decreased up to 34.70% in
  • FENFURO-treated group whereas on-going anti- diabetic therapy caused 21.51% decrease in HbA1c levels. These HbA1c levels came to normal range (Good control range – 4.5-6.3%) in FENFURO-treated study population whereas they were still abnormal (Poor control levels – 7.6%) in on-going anti-diabetic therapy treated population till 12 weeks of treatment.

Safety Conclusions

  • No significant change in the liver function tests (serum glutamic-oxaloacetic transaminase, serum glutamic-pyruvic transaminase, alkaline phosphates activities and serum bilirubin levels) was observed on completion of the treatment.
  • No significant change in the serum urea levels and creatinine levels was observed on completion of the treatment.
  • No significant change in the hematological parameters was observed on completion of the treatment.

 

Efficacy conclusions

  •  A significant decrease in HbA1C levels was observed as compared to respective baseline value.
  •  FENFURO caused significant reduction in the fasting blood sugar levels.
  •  FENFURO caused significant reduction in the post prandial (PP) blood sugar levels as compared to Placebo group as well as compared to respective baseline value.
  •  83% of the patients reported decrease in fasting sugar levels in FENFURO treated group as compared to 62% in Placebo treated group.
  •  89% of the patients reported decrease in PP sugar levels in FENFURO treated group as compared to 72% of the patients in the Placebo treated group.
  •  48.8% of the patients reported reduced dosage of anti-diabetic therapy in FENFURO treated group, where as 18.05% of the patients reported reduced dosage of anti-diabetic therapy in Placebo treated group.

Safety conclusions

  •  No significant change in serum SGOT, SGPT & ALP activities was observed, indicating FENFURO was safe for liver functioning.
  •  No significant change in blood urea nitrogen and creatinine levels was observed indicating FENFURO was safe for kidney functioning.
  •  No significant change in hematological parameters was observed.
  •  Keeping hematological and biochemical results in view, investigational product was safe for consumption.

Ingredients: Each capsule contains 500 mg Furostanolic Saponins.

Dosage: One capsule, 1-3 times daily or as directed by your physician (For details, please refer to the Dosage page)

Unique features of FENFUROTM

  • FENFUROTM is a first of its kind product derived from single herb with proven results for maintaining blood sugar levels.
  • Scientific Research supports the non-toxicity of the product.
  • Scientifically processed without affecting the chemical properties of the active ingredient to give maximum benefit.
fenfuro-clinically evaluation

*Complete clinical data available on request.

Innovative product FENFURO is now protected with following patents;

DELIVERY

We deliver our products across India & abroad.
Time to ship – immediate(Delivery time could vary depending on your location).
Write to us at customercare@chereso.net or call us +91-9915002390.

Additional information

Dimensions 80.0 × 65.5 × 87.0 in

Reviews

There are no reviews yet.

Be the first to review “FENFURO”

Your email address will not be published. Required fields are marked *

Post comment

You may also like…